Mesoblast's Ryoncil generated $12.4M in Q1 sales, up from $2.1M in the launch quarter. Management targets 100 patients by year-end, with adult-label data due H2 2025.
Alpha Score of 67 reflects moderate overall profile with strong momentum, strong value, weak quality, moderate sentiment.
Mesoblast reported its first full quarter of Ryoncil revenue since the FDA approved the cell therapy for steroid-refractory acute graft-versus-host disease in children. The company booked $12.4 million in net sales for the March quarter, up from $2.1 million in the December launch period. Management guided for sequential growth through calendar 2025, with a target of treating 100 patients by year-end.
The commercial ramp matters because Ryoncil is Mesoblast's only marketed product. The company has burned through roughly $1.2 billion in cumulative operating losses since inception, funded largely by equity raises and debt. A sustained revenue trajectory would reduce the need for dilutive capital and give the balance sheet breathing room.
Mesoblast is also pursuing an expanded label for Ryoncil in adults with the same indication. A phase 3 trial is fully enrolled, with top-line data expected in the second half of 2025. If positive, the addressable patient population would roughly triple.
On the cost side, Mesoblast reported a gross margin of 72% on Ryoncil sales, above the 65% the company had modeled internally. Manufacturing yields improved after a process change implemented in late 2024, management said on the earnings call.
The stock trades at about 8x trailing revenue on a run-rate basis, a discount to cell-therapy peers like bluebird bio and Kite Pharma, which trade at 12-15x. The gap narrows if Ryoncil hits the 100-patient target by December.
Cash and equivalents stood at $89 million at quarter-end, enough to fund operations into early 2026 without additional financing, the company said. That timeline extends if revenue continues to grow.
Drafted by a large language model from the source reporting linked above, then screened by automated publishing checks. It is not read by a journalist before publication. Some articles cite our Alpha Score. Verify prices and figures against the original source. Educational coverage, not personalized advice.